LAVAL, QC, April 23 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
announced the dates and times of its first quarter fiscal 2009 results
conference call and Annual Meeting of Shareholders.
First Quarter Results Conference Call
On Thursday, May 7 at 8:30 a.m. (ET) Labopharm will host a conference
call to discuss its first quarter 2009 financial results. Labopharm will
report its first quarter 2009 financial results via news release at
approximately 7:00 a.m. the same day.
To access the conference call by telephone, dial 416-644-3420 or
1-800-732-0232. Please connect approximately 15 minutes prior to the beginning
of the call to ensure participation. The conference call will be archived for
replay until Thursday, May 14, 2009 at midnight. To access the archived
conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation
number 21303738 followed by the number sign.
A live audio webcast of the conference call will be available at
www.labopharm.com. Please connect at least 15 minutes prior to the conference
call to ensure adequate time for any software download that may be required to
join the webcast. The webcast will be archived at the above web site for 30
Annual Meeting of Shareholders
Labopharm will hold its Annual Meeting of Shareholders on Thursday, May 7
at 11:00 am ET at the Montreal Museum of Fine Arts, Maxwell-Cummings
Auditorium, 1379 Sherbrooke Street West, Montreal, Quebec.
A live webcast of the meeting will be available at www.labopharm.com.
Please connect at least 15 minutes prior to the meeting to ensure adequate
time for any software download that may be required to join the webcast. The
webcast will be archived at the above website for 30 days.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
being commercially launched in key markets globally and its second product, a
novel formulation of trazodone for the treatment of major depressive disorder,
is under regulatory review by the FDA. The Company also has a robust pipeline
of follow-on products in both pre-clinical and clinical development.
Labopharm's vision is to become an integrated, international, specialty
pharmaceutical company with the capability to internally develop and
commercialize its own products. For more information, please visit
For further information:
For further information: At Labopharm: Mark D'Souza, Senior
Vice-President and Chief Financial Officer, Tel: (450) 686-0207; At The
Equicom Group: Jason Hogan, Media and Investor Relations, Tel: (416) 815-0700,
email@example.com; French: Joe Racanelli, Tel: (514) 844-7997,